Phase I clinical and pharmacological study of oral methoxymorpholinyl doxorubicin (PNU 152243).
Sessa C, Zucchetti M, Ghielmini M, Bauer J, D'Incalci M, de Jong J, Naegele H, Rossi S, Pacciarini MA, Domenigoni L, Cavalli F.
Sessa C, et al. Among authors: cavalli f.
Cancer Chemother Pharmacol. 1999;44(5):403-10. doi: 10.1007/s002800050996.
Cancer Chemother Pharmacol. 1999.
PMID: 10501914
Clinical Trial.